Eli Lilly Joins Chase for Hot Inflammation Target, Paying $100M for Rights to CSL DrugNews DeskFebruary 18, 20260 Eli Lilly has been scouting for drugs to follow the trail blazed by its blockbuster cardiometabolic medicines. Its latest pipeline-building…